Abstract | BACKGROUND: METHODS: A total of 51 patients presenting with pelvic malignancies with cancerous pudendal neuralgia were selected, and random number table method was used to allocate them to either the experimental group (n=27) or control group (n=24). The control group was treated with OxyContin combined with Pregabalin, and the experimental group was treated with Celecoxib on the basis of the control group. RESULTS: At 24 hours after treatment, the clinical effective rate of the experimental group was 92.6%, which was significantly higher than the 66.7% of the control group (P<0.05). The numerical rating scale (NRS) scores of the 2 groups of participants on the 7th and 14th days after treatment were lower than before treatment (P<0.05), and the NRS scores of the participants in the experimental group had decreased more significantly. At the same time, the average daily consumption of OxyContin on the 7th and 14th day of the experimental group was lower than that of the control group (P<0.05). Compared with the control group, the incidence of constipation and dysuria in the experimental group was significantly reduced (P<0.05). Co-occurring in both groups during treatment, 10 participants with urinary dysfunction were treated with tamsulosin hydrochloride sustained-release capsules, no urinary retention occurred, catheterization was avoided, tamsulosin hydrochloride sustained-release capsules could be stopped after 1 week, and urination was smooth (P<0.05). After treatment, the quality of life of the 2 groups of participants had improved compared to before treatment, and the improvement was more significant in the experimental group. CONCLUSIONS: TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100046045.
|
Authors | Junjie Hou, Yifan Lin, Yanqiu Fang, Xiaonan Li, Xiao-Nan Li, Ying Yang, Ning Liu, Xianzhuo Jiang, Yingying Yu, Ying Zhou, Xuguang Mi, Zhiqiang Ni, Xiaodan Lu, Ning-Yi Jin |
Journal | Annals of palliative medicine
(Ann Palliat Med)
Vol. 10
Issue 5
Pg. 5754-5762
(May 2021)
ISSN: 2224-5839 [Electronic] China |
PMID | 33977736
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Pharmaceutical Preparations
- Pregabalin
|
Topics |
- Humans
- Pharmaceutical Preparations
- Pregabalin
(adverse effects)
- Pudendal Neuralgia
- Quality of Life
- Treatment Outcome
|